Therapeutic effect and safety of cilostazol combined clopidogrel and aspirin on aged patients after PCI
10.3969/j.issn.1008-0074.2016.01.21
- VernacularTitle:西洛他唑联合氯吡格雷血小板治疗对 PCI 术后老年患者的疗效及安全性
- Author:
Sikun WANG
;
Yi JIANG
;
Chunming WANG
;
Hao YU
;
Su CHEN
;
Xiaojun HU
- Publication Type:Journal Article
- Keywords:
Angioplasty,balloon,coronary;
Hemorrhage;
Platelet aggregation inhibitors;
Cilostazol
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2016;25(1):75-78
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore therapeutic effect and safety of cilostazol combined clopidogrel +aspirin on aged pa‐tients after percutaneous coronary intervention (PCI) .Methods :A total of 100 aged patients with coronary heart disease undergoing PCI were randomly divided into routine treatment group (n=52 ,received aspirin and clopidogrel antiplatelet therapy) and cilostazol group (n= 48 ,received cilostazol therapy based on routine treatment group ) . Turbidimetry was used to measure platelet aggregation rate (PAR );PAR and mean platelet volume (MPV ) were compared between two groups before ,one week and one month after PCI .All subjects were followed up for six months ,incidence rates of major adverse cardiovascular events (MACE) and hemorrhage events were compared be‐tween two groups .Results:There were no significant difference in MPV and PAR between two groups before PCI . Compared with routine treatment group ,PAR significantly reduced [one week after PCI :(48.7 ± 6.3)% vs .(43.5 ± 5.7)% ,one month after PCI :(46.8 ± 5.8)% vs .(42.4 ± 5.4)% ] in cilostazol group , P<0.05 both . After six-month follow-up ,there was no significant difference in total incidence rate of MACE (16.7% vs .17.3% ) be‐tween cilostazol group and routine treatment group , P>0.05;incidence rate of hemorrhage in cilostazol group was significantly lower than that of routine treatment group (6.25% vs .19.23% , P< 0.01) .Conclusion:Compared with clopidogrel+aspirin therapy ,cilostazol combined clopidogrel+aspirin can more significantly inhibit platelet ag‐gregation ,and significantly reduce hemorrhage events ,so they are safe and effective in aged patients with coronary heart disease undergoing PCI .
